X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (128) 128
female (87) 87
endocrinology & metabolism (84) 84
index medicus (79) 79
male (75) 75
middle aged (75) 75
adult (53) 53
aged (45) 45
type 2 diabetes (37) 37
risk factors (32) 32
diabetes (29) 29
mortality (29) 29
risk (25) 25
nutrition & dietetics (22) 22
body mass index (18) 18
diabetes mellitus (18) 18
obesity (17) 17
cardiac & cardiovascular systems (16) 16
endocrinology (16) 16
albuminuria (15) 15
animals (15) 15
glomerular filtration rate (15) 15
adolescent (14) 14
cardiovascular disease (14) 14
cardiovascular diseases (14) 14
diabetes mellitus, type 2 - blood (14) 14
disease (14) 14
glucose (14) 14
insulin (14) 14
research (14) 14
blood pressure (13) 13
cross-sectional studies (13) 13
diabetes mellitus, type 2 - drug therapy (13) 13
internal medicine (13) 13
mellitus (13) 13
nephropathy (13) 13
prevalence (13) 13
diabetes mellitus, type 2 - complications (12) 12
gene-expression (12) 12
glomerular-filtration-rate (12) 12
medicine & public health (12) 12
metaanalysis (12) 12
treatment outcome (12) 12
urology & nephrology (12) 12
abridged index medicus (11) 11
analysis (11) 11
expression (11) 11
metabolic diseases (11) 11
thyroid neoplasms - pathology (11) 11
complications (10) 10
diabetes mellitus, type 2 - epidemiology (10) 10
hypertension (10) 10
hypoglycemic agents - therapeutic use (10) 10
metabolic syndrome (10) 10
time factors (10) 10
aged, 80 and over (9) 9
association (9) 9
blood glucose - metabolism (9) 9
care and treatment (9) 9
cohort studies (9) 9
development and progression (9) 9
diabetes mellitus, type 2 - physiopathology (9) 9
insulin resistance (9) 9
insulin-resistance (9) 9
management (9) 9
medicine, general & internal (9) 9
metabolism (9) 9
mice (9) 9
oxidative stress (9) 9
rats (9) 9
blood-pressure (8) 8
cardiovascular (8) 8
cardiovascular diseases - epidemiology (8) 8
cardiovascular diseases - mortality (8) 8
cardiovascular-disease (8) 8
diabetes mellitus, type 2 - mortality (8) 8
follow-up studies (8) 8
italy - epidemiology (8) 8
kidney diseases (8) 8
medicine (8) 8
microalbuminuria (8) 8
obesity - blood (8) 8
transplantation (8) 8
adipose tissue - metabolism (7) 7
cardiovascular risk (7) 7
cells, cultured (7) 7
chronic kidney-disease (7) 7
dependent diabetes-mellitus (7) 7
differentiation (7) 7
europe (7) 7
genetic aspects (7) 7
glycemic control (7) 7
health aspects (7) 7
impact (7) 7
insulin - blood (7) 7
men (7) 7
myocardial-infarction (7) 7
obstetrics & gynecology (7) 7
oncology (7) 7
peripheral vascular disease (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 323 - 334
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 22, pp. 2117 - 2128
Journal Article
European Heart Journal, ISSN 0195-668X, 05/2016, Volume 37, Issue 19, pp. 1526 - 1534
Aims We previously reported that in the EMPA-REG OUTCOME(R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse... 
Cardiovascular disease | Mortality | Hospitalization | CARDIAC & CARDIOVASCULAR SYSTEMS | SAFETY | GUIDELINES | MELLITUS | COTRANSPORTER 2 INHIBITION | BLOOD-PRESSURE | INSULIN | DISEASES | COLLABORATION | DOUBLE-BLIND | Fast Track | Aha Fasttrack | Editor's Choice
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
Medicine(all) | MEDICINE, GENERAL & INTERNAL | RISK | EVENT LOWERING EXSCEL | GLUCOSE CONTROL | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Circulation, ISSN 0009-7322, 01/2018, Volume 137, Issue 2, pp. 119 - 129
BACKGROUND:Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus... 
Treatment outcome | Hospitalization | Kidney diseases | Mortality | Diabetes mellitus type 2 | Sodiumglucose transporter 2 | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | hospitalization | SAFETY | HEART-FAILURE | sodium-glucose transporter 2 | RISK | DEATH | MECHANISMS | treatment outcome | IMPACT | kidney diseases | mortality | PERIPHERAL VASCULAR DISEASE | diabetes mellitus, type 2 | SGLT2 INHIBITION | PROGRESSION | Prevalence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Cause of Death | Renal Insufficiency, Chronic - drug therapy | Albuminuria - physiopathology | Glomerular Filtration Rate - drug effects | Benzhydryl Compounds - adverse effects | Albuminuria - mortality | Time Factors | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Female | Glucosides - therapeutic use | Renal Insufficiency, Chronic - diagnosis | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Kidney - physiopathology | Cardiovascular Diseases - diagnosis | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - physiopathology | Kidney - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Risk Factors | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - physiopathology | Diabetes Mellitus, Type 2 - mortality | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment
Journal Article
Stroke, ISSN 0039-2499, 05/2017, Volume 48, Issue 5, pp. 1218 - 1225
Journal Article